Nuclear medicine (NM) educators face a pivotal time of rapid scientific innovation and expansion of theranostic possibilities, rising volumes, staffing shortages, and a call for more high-quality ...
Journal of Nuclear Medicine Technology June 2026, jnmt.126.272159; DOI: https://doi.org/10.2967/jnmt.126.272159 ...
Prostate-specific membrane antigen (PSMA) has fundamentally reshaped prostate cancer imaging and therapy, delivering an unprecedented combination of high lesion conspicuity, broad clinical ...
Prostate cancer is a rapidly expanding area for radiopharmaceutical therapy, primarily driven by prostate-specific membrane antigen–targeted imaging and therapy. This growth necessitates new workflows ...
The Prostate Cancer Working Group 4 guidelines (PCWG4) represent a significant evolution in the framework used to evaluate prostate cancer progression and treatment response in clinical trials.
Journal of Nuclear Medicine Technology April 2026, jnmt.125.271114; DOI: https://doi.org/10.2967/jnmt.125.271114 ...
Journal of Nuclear Medicine Technology March 2026, jnmt.125.271409; DOI: https://doi.org/10.2967/jnmt.125.271409 ...
Journal of Nuclear Medicine Technology February 2026, jnmt.125.271835; DOI: https://doi.org/10.2967/jnmt.125.271835 ...
Journal of Nuclear Medicine Technology January 2026, jnmt.125.270563; DOI: https://doi.org/10.2967/jnmt.125.270563 ...
The widespread success of 177Lu-PSMA-617 for prostate cancer has generated unprecedented volume in theranostics. Prostate-specific membrane antigen–targeted theranostics is possibly the most complex ...
Theranostics, the integration of diagnostic imaging with targeted radiopharmaceutical therapy, is reshaping the practice of nuclear medicine worldwide. This article provides a global perspective on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results